Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Primary Osteoarthritis Affecting a Single Knee
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Funapide (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 30 Sep 2016 Primary endpoint has not been met. (Change from baseline to week 4 in pain on walking (WOMAC question 1))
- 30 Sep 2016 Results presented at the 16th World Congress on Pain
- 01 Jul 2015 Top-line results published in a Teva Pharmaceutical Industries and Xenon Pharmaceuticals media release from.